Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report) today and set a price target of $213.00.
Jason Gerberry has given his Buy rating due to a combination of factors including the promising potential of Jazz Pharmaceuticals’ Ziihera/zani drug, which is currently undervalued. The drug is expected to show significant results in the treatment of gastric and breast cancers, with a potential market of over $2 billion in peak US sales. The Phase 3 data for gastric cancer is anticipated to be positive, with a high probability of success, and could lead to a re-evaluation of Jazz’s stock value.
Additionally, Jazz Pharmaceuticals is currently trading at a discount compared to its peers, providing an attractive investment opportunity. The delay in the gastric cancer trial results is perceived as neutral or potentially beneficial, based on historical data. The strength of the Phase 2 study data for Ziihera/zani further supports the potential for success in Phase 3 trials, making Jazz Pharmaceuticals a compelling buy at its current price.
In another report released on March 10, H.C. Wainwright also reiterated a Buy rating on the stock with a $217.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com